Scientific Presentations

ARVO 2021 Annual Meeting | May 2021

5-Year Results of a Home Monitoring Device in Study Participants at High Risk for Neovascular Age-related Macular Degeneration

Marcus T. Altman

These data over 5 years suggest a large proportion of incident neovascular AMD cases were detected by home monitoring, and eyes monitored by the device had good visual acuity at time of CNV detection. In this study, the device showed a 22% false negative rate.

FDA Intended Use

ForeseeHome has not been approved by FDA for use other than described in the following Indication for Use: The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration as an aid in monitoring progression of disease factors causing metamorphopsia including, but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.

Media enquiries? Reach out to our Media Contact